satavaptan satavaptan satavaptan (inn; developmental code name sr121463, former tentative brand name aquilda) is a vasopressin-2 receptor antagonist which was investigation by sanofi-aventis and was under development for the treatment of hyponatremia. it was also being studied for the treatment of ascites. development was discontinued in 2009. satavaptanclinical dataatc codenoneidentifiers iupac name n-(tert-butyl)-4--3-methoxybenzamide cas number185913-78-4 ypubchem cid9810773chemspider32699105 nuniiajs8s3p31hecha infocard100.211.853 chemical and physical dataformulac33h45n3o8smolar mass643.80 g·mol−13d model (jsmol)interactive image smiles c1coccn1cco2cc(cc2)3c4cc(occ)ccc4n(c3=o)s(=o)(=o)c5ccc(cc5oc)c(=o)nc(c)(c)c inchi inchi=1s/c33h45n3o8s/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24h,6,11-20h2,1-5h3,(h,34,37)/t24-,33+ nkey:qkxjwfokvqwedz-vccceuobsa-n n ny (what is this?) (verify)